View Financial HealthPacific Software 配当と自社株買い配当金 基準チェック /06Pacific Software配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Nov 12Pacific Software, Inc. (OTCPK:PFSF) acquired 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc.Pacific Software, Inc. (OTCPK:PFSF) agreed to acquire 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc. on August 25, 2025. As part of the acquisition, the current management team of 107 Canada is expected to assume leadership roles in the company and elect a new Board of Directors of Pacific Software Inc. which may consider a name change to PurMinds Enterprises, if available. Pacific Software, Inc. (OTCPK:PFSF) completed the acquisition of 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc. on November 11, 2025. The common stock is now quoted on the OTC market platform. Following completion, the PurMinds management team has assumed leadership roles and is considering a corporate name change to PurMinds Enterprises pending approval by FINRA.お知らせ • Jul 23Robert Schiestl Joins Pacific Software Inc. as Chief Science AdvisorPacific Software Inc. announced the appointment of Professor Dr. Robert Schiestl Ph.D. as its Chief Science Advisor (CSA), effective immediately. Dr. Robert Schiestl is a distinguished scientist who received his Ph.D. from the University of Vienna, Austria with an extensive background in molecular toxicology, cancer prevention, and genomics. He was previously Assistant and Associate Professor in the Department of Cancer Research and later Toxicology at the Harvard School of Public Health. He is currently Professor Emeritus of Pathology, Environmental Health Sciences and Radiation Oncology at UCLA. He was a Director of the UCLA Center for Environmental Genomics, member of the UCLA Cancer Center and Occupational and Environmental Health Sciences. He was also a member of the Interdepartmental Program in molecular Toxicology (advisory committee) at UCLA. Dr. Schiestl has authored over 200 peer-reviewed publications and has been recognized with numerous awards for his research and contributions to science. Dr. Schiestl's work focuses on the mechanisms of genetic stability and the development of strategies to prevent genetic diseases and cancer. His research has provided significant insights into the field of oxidative stress and its impact on health, which aligns perfectly with the company’s mission to develop innovative skincare products and science-based dietary supplements. Dr. Schiestl’s Achievements and Contributions Include: Over 200 peer-reviewed publications in scientific journals, 9 press releases and 16 patents and 6 companies. Recipient of numerous awards including Outstanding Leadership Award in Healthcare 2022, Outstanding Visionary Award in Healthcare 2023, Outstanding Organization Award in Healthcare 2024, Outstanding Education Award 2023, The Outstanding MORE Leadership Award (Money and Real Estate) in 2023, Outstanding CXO Award 2024 as best CEO, the Outstanding Leadership Award in Internet 2024, The Best Speakership Award at The International Conference on Nursery, Patient Safety and Healthcare 2023. Pioneering research in genetic stability and cancer prevention and Health. Development of novel strategies to combat oxidative stress-related health issues.決済の安定と成長配当データの取得安定した配当: PFSFの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PFSFの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Pacific Software 配当利回り対市場PFSF 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PFSF)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Software)0.9%アナリスト予想 (PFSF) (最長3年)n/a注目すべき配当: PFSFは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PFSFは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PFSFの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PFSFが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 03:51終値2026/05/18 00:00収益2021/06/30年間収益2020/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pacific Software, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 12Pacific Software, Inc. (OTCPK:PFSF) acquired 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc.Pacific Software, Inc. (OTCPK:PFSF) agreed to acquire 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc. on August 25, 2025. As part of the acquisition, the current management team of 107 Canada is expected to assume leadership roles in the company and elect a new Board of Directors of Pacific Software Inc. which may consider a name change to PurMinds Enterprises, if available. Pacific Software, Inc. (OTCPK:PFSF) completed the acquisition of 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc. on November 11, 2025. The common stock is now quoted on the OTC market platform. Following completion, the PurMinds management team has assumed leadership roles and is considering a corporate name change to PurMinds Enterprises pending approval by FINRA.
お知らせ • Jul 23Robert Schiestl Joins Pacific Software Inc. as Chief Science AdvisorPacific Software Inc. announced the appointment of Professor Dr. Robert Schiestl Ph.D. as its Chief Science Advisor (CSA), effective immediately. Dr. Robert Schiestl is a distinguished scientist who received his Ph.D. from the University of Vienna, Austria with an extensive background in molecular toxicology, cancer prevention, and genomics. He was previously Assistant and Associate Professor in the Department of Cancer Research and later Toxicology at the Harvard School of Public Health. He is currently Professor Emeritus of Pathology, Environmental Health Sciences and Radiation Oncology at UCLA. He was a Director of the UCLA Center for Environmental Genomics, member of the UCLA Cancer Center and Occupational and Environmental Health Sciences. He was also a member of the Interdepartmental Program in molecular Toxicology (advisory committee) at UCLA. Dr. Schiestl has authored over 200 peer-reviewed publications and has been recognized with numerous awards for his research and contributions to science. Dr. Schiestl's work focuses on the mechanisms of genetic stability and the development of strategies to prevent genetic diseases and cancer. His research has provided significant insights into the field of oxidative stress and its impact on health, which aligns perfectly with the company’s mission to develop innovative skincare products and science-based dietary supplements. Dr. Schiestl’s Achievements and Contributions Include: Over 200 peer-reviewed publications in scientific journals, 9 press releases and 16 patents and 6 companies. Recipient of numerous awards including Outstanding Leadership Award in Healthcare 2022, Outstanding Visionary Award in Healthcare 2023, Outstanding Organization Award in Healthcare 2024, Outstanding Education Award 2023, The Outstanding MORE Leadership Award (Money and Real Estate) in 2023, Outstanding CXO Award 2024 as best CEO, the Outstanding Leadership Award in Internet 2024, The Best Speakership Award at The International Conference on Nursery, Patient Safety and Healthcare 2023. Pioneering research in genetic stability and cancer prevention and Health. Development of novel strategies to combat oxidative stress-related health issues.